Full Text Journal Articles by
Author Federico Caligaris Cappio

Advertisement

Find full text journal articles






Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Priyanka Banerjee, Ronghua Zhang, Cristina Ivan, Giovanni Galletti, Karen Clise-Dwyer, Federica Barbaglio, Lydia Scarfò, Miguel Aracil, Christian Klein, William Wierda, William Plunkett, Federico Caligaris-Cappio, Varsha Gandhi, Michael J Keating, Maria Teresa S Bertilaccio,

Chronic lymphocytic leukemia (CLL) is a B-cell neoplasia characterized by protumor immune dysregulation involving nonmalignant cells of the microenvironment, including T lymphocytes and tumor-associated myeloid cells. Although therapeutic agents have improved treatment options for CLL, many patients still fail to respond. Some patients also show immunosuppression. We have investigated trabectedin, ... Read more >>

Cancer Immunol Res (Cancer immunology research)
[2019, 7(12):2036-2051]

Cited: 0 times

View full text PDF listing >>



Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.

Michael Steurer, Marco Montillo, Lydia Scarfò, Francesca R Mauro, Johannes Andel, Sophie Wildner, Livio Trentin, Ann Janssens, Sonja Burgstaller, Anna Frömming, Thomas Dümmler, Kai Riecke, Matthias Baumann, Diana Beyer, Stéphanie Vauléon, Paolo Ghia, Robin Foà, Federico Caligaris-Cappio, Marco Gobbi,

Olaptesed pegol (NOX-A12) is a pegylated structured L-oligoribonucleotide that binds and neutralizes CXCL12, a chemokine tightly regulating the life cycle of chronic lymphocytic leukemia cells. The resulting inhibition of CXCR4 and CXCR7 signaling reduces the protective activity of the bone marrow and lymph node microenvironment. CXCL12 inhibition mobilizes chronic lymphocytic ... Read more >>

Haematologica (Haematologica)
[2019, 104(10):2053-2060]

Cited: 0 times

View full text PDF listing >>



Advertisement

IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development.

Federica Riva, Maurilio Ponzoni, Domenico Supino, Maria Teresa Sabrina Bertilaccio, Nadia Polentarutti, Matteo Massara, Fabio Pasqualini, Roberta Carriero, Anna Innocenzi, Achille Anselmo, Tania Veliz-Rodriguez, Giorgia Simonetti, Hans-Joachim Anders, Federico Caligaris-Cappio, Alberto Mantovani, Marta Muzio, Cecilia Garlanda,

Chronic inflammation, including that driven by autoimmunity, is associated with the development of B-cell lymphomas. IL1R8 is a regulatory receptor belonging to the IL1R family, which negatively regulates NF-κB activation following stimulation of IL1R or Toll-like receptor family members. IL1R8 deficiency is associated with the development of severe autoimmune lupus-like ... Read more >>

Cancer Immunol Res (Cancer immunology research)
[2019, 7(6):874-885]

Cited: 0 times

View full text PDF listing >>



A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression.

Diego Farinello, Monika Wozińska, Elisa Lenti, Luca Genovese, Silvia Bianchessi, Edoardo Migliori, Nicolò Sacchetti, Alessia di Lillo, Maria Teresa Sabrina Bertilaccio, Claudia de Lalla, Roberta Valsecchi, Sabrina Bascones Gleave, David Lligé, Cristina Scielzo, Laura Mauri, Maria Grazia Ciampa, Lydia Scarfò, Rosa Bernardi, Dejan Lazarevic, Blanca Gonzalez-Farre, Lucia Bongiovanni, Elias Campo, Andrea Cerutti, Maurilio Ponzoni, Linda Pattini, Federico Caligaris-Cappio, Paolo Ghia, Andrea Brendolan,

In chronic lymphocytic leukemia (CLL), the non-hematopoietic stromal microenvironment plays a critical role in promoting tumor cell recruitment, activation, survival, and expansion. However, the nature of the stromal cells and molecular pathways involved remain largely unknown. Here, we demonstrate that leukemic B lymphocytes induce the activation of retinoid acid synthesis ... Read more >>

Nat Commun (Nature communications)
[2018, 9(1):1787]

Cited: 2 times

View full text PDF listing >>



iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Michael Hallek, Bruce D Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R Rai, John C Byrd, Barbara Eichhorst, Susan O'Brien, Tadeusz Robak, John F Seymour, Thomas J Kipps,

The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with ... Read more >>

Blood (Blood)
[2018, 131(25):2745-2760]

Cited: 57 times

View full text PDF listing >>



Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.

Daniela Belloni, Silvia Heltai, Maurilio Ponzoni, Antonello Villa, Barbara Vergani, Lorenza Pecciarini, Magda Marcatti, Stefania Girlanda, Giovanni Tonon, Fabio Ciceri, Federico Caligaris-Cappio, Marina Ferrarini, Elisabetta Ferrero,

Multiple myeloma develops primarily inside the bone marrow microenvironment, that confers pro-survival signals and drug resistance. 3D cultures that reproduce multiple myeloma-bone marrow interactions are needed to fully investigate multiple myeloma pathogenesis and response to drugs. To this purpose, we exploited the 3D Rotary Cell Culture System bioreactor technology for ... Read more >>

Haematologica (Haematologica)
[2018, 103(4):707-716]

Cited: 4 times

View full text PDF listing >>



Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens.

Nereida Jiménez de Oya, Marco De Giovanni, Jessica Fioravanti, Rudolf Übelhart, Pietro Di Lucia, Amleto Fiocchi, Stefano Iacovelli, Dimitar G Efremov, Federico Caligaris-Cappio, Hassan Jumaa, Paolo Ghia, Luca G Guidotti, Matteo Iannacone,

Several lines of evidence indirectly suggest that antigenic stimulation through the B-cell receptor (BCR) supports chronic lymphocytic leukemia (CLL) development. In addition to self-antigens, a number of microbial antigens have been proposed to contribute to the selection of the immunoglobulins expressed in CLL. How pathogen-specific BCRs drive CLL development remains, ... Read more >>

EMBO Mol Med (EMBO molecular medicine)
[2017, 9(11):1482-1490]

Cited: 1 time

View full text PDF listing >>



Immunotherapy in lymphoma.

Stephen M Ansell, Federico Caligaris-Cappio, David G Maloney,

Hematol Oncol (Hematological oncology)
[2017, 35 Suppl 1:88-91]

Cited: 0 times

View full text PDF listing >>



Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.

Francesca Gorini, Laura Azzimonti, Gloria Delfanti, Lydia Scarfò, Cristina Scielzo, Maria Teresa Bertilaccio, Pamela Ranghetti, Alessandro Gulino, Claudio Doglioni, Arianna Di Napoli, Miriam Capri, Claudio Franceschi, Federico Caligaris-Cappio, Paolo Ghia, Matteo Bellone, Paolo Dellabona, Giulia Casorati, Claudia de Lalla,

Chronic lymphocytic leukemia (CLL) is characterized by the expansion of malignant CD5+ B lymphocytes in blood, bone marrow, and lymphoid organs. CD1d-restricted invariant natural killer T (iNKT) cells are innate-like T lymphocytes strongly implicated in tumor surveillance. We investigated the impact of iNKT cells in the natural history of the ... Read more >>

Blood (Blood)
[2017, 129(26):3440-3451]

Cited: 16 times

View full text PDF listing >>



Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

Elisa Ten Hacken, Mariela Sivina, Ekaterina Kim, Susan O'Brien, William G Wierda, Alessandra Ferrajoli, Zeev Estrov, Michael J Keating, Thomas Oellerich, Cristina Scielzo, Paolo Ghia, Federico Caligaris-Cappio, Jan A Burger,

BCR signaling is a central pathogenetic pathway in chronic lymphocytic leukemia (CLL). Most CLL cells express BCRs of IgM and IgD isotypes, but the contribution of these isotypes to functional responses remains incompletely defined. We therefore investigated differences between IgM and IgD signaling in freshly isolated peripheral blood CLL cells ... Read more >>

J. Immunol. (Journal of immunology (Baltimore, Md. : 1950))
[2016, 197(6):2522-2531]

Cited: 8 times

View full text PDF listing >>



Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models.

Mimma Bianco, Anna Gasparri, Luca Generoso, Emma Assi, Barbara Colombo, Lydia Scarfò, Maria T S Bertilaccio, Cristina Scielzo, Pamela Ranghetti, Eleonora Dondossola, Maurilio Ponzoni, Federico Caligaris-Cappio, Paolo Ghia, Angelo Corti,

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of leukemic B cells in peripheral blood, bone marrow (BM) and lymphoid tissues, and by their recirculation between these compartments. We observed that circulating chromogranin A (CgA) and its N-terminal fragment (called vasostatin-1, CgA1-76), two neuroendocrine secretory polypeptides that enhance the ... Read more >>

Oncotarget (Oncotarget)
[2016, 7(27):41725-41736]

Cited: 4 times

View full text PDF listing >>



HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.

Roberta Valsecchi, Nadia Coltella, Daniela Belloni, Manfredi Ponente, Elisa Ten Hacken, Cristina Scielzo, Lydia Scarfò, Maria Teresa Sabrina Bertilaccio, Paola Brambilla, Elisa Lenti, Filippo Martinelli Boneschi, Andrea Brendolan, Elisabetta Ferrero, Marina Ferrarini, Paolo Ghia, Giovanni Tonon, Maurilio Ponzoni, Federico Caligaris-Cappio, Rosa Bernardi,

Hypoxia-inducible transcription factors (HIFs) regulate a wide array of adaptive responses to hypoxia and are often activated in solid tumors and hematologic malignancies due to intratumoral hypoxia and emerging new layers of regulation. We found that in chronic lymphocytic leukemia (CLL), HIF-1α is a novel regulator of the interaction of ... Read more >>

Blood (Blood)
[2016, 127(16):1987-1997]

Cited: 18 times

View full text PDF listing >>



Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

Giovanni Galletti, Cristina Scielzo, Federica Barbaglio, Tania Véliz Rodriguez, Michela Riba, Dejan Lazarevic, Davide Cittaro, Giorgia Simonetti, Pamela Ranghetti, Lydia Scarfò, Maurilio Ponzoni, Martina Rocchi, Angelo Corti, Achille Anselmo, Nico van Rooijen, Christian Klein, Carola H Ries, Paolo Ghia, Michele De Palma, Federico Caligaris-Cappio, Maria Teresa Sabrina Bertilaccio,

The role of monocytes/macrophages in the development and progression of chronic lymphocytic leukemia (CLL) is poorly understood. Transcriptomic analyses show that monocytes/macrophages and leukemic cells cross talk during CLL progression. Macrophage depletion impairs CLL engraftment, drastically reduces leukemic growth, and favorably impacts mouse survival. Targeting of macrophages by either CSF1R ... Read more >>

Cell Rep (Cell reports)
[2016, 14(7):1748-1760]

Cited: 25 times

View full text PDF listing >>



Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.

Mimma Bianco, Anna Maria Gasparri, Barbara Colombo, Flavio Curnis, Stefania Girlanda, Maurilio Ponzoni, Maria Teresa Sabrina Bertilaccio, Arianna Calcinotto, Angelina Sacchi, Elisabetta Ferrero, Marina Ferrarini, Marta Chesi, P Leif Bergsagel, Matteo Bellone, Giovanni Tonon, Fabio Ciceri, Magda Marcatti, Federico Caligaris-Cappio, Angelo Corti,

Angiogenesis has been postulated to be critical for the pathogenesis of multiple myeloma, a neoplastic disease characterized by abnormal proliferation of malignant plasma cells in the bone marrow (BM). Cleavage of the N- and C-terminal regions of circulating chromogranin A (CgA, CHGA), classically an antiangiogenic protein, can activate latent antiangiogenic ... Read more >>

Cancer Res. (Cancer research)
[2016, 76(7):1781-1791]

Cited: 11 times

View full text PDF listing >>



Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Eleonora Fonte, Andreas Agathangelidis, Daniele Reverberi, Stavroula Ntoufa, Lydia Scarfò, Pamela Ranghetti, Giovanna Cutrona, Alessandra Tedeschi, Aliki Xochelli, Federico Caligaris-Cappio, Maurilio Ponzoni, Chrysoula Belessi, Zadie Davis, Miguel A Piris, David Oscier, Paolo Ghia, Kostas Stamatopoulos, Marta Muzio,

Recent studies on splenic marginal zone lymphoma identified distinct mutations in genes belonging to the B-cell receptor and Toll-like receptor signaling pathways, thus pointing to their potential implication in the biology of the disease. However, limited data is available regarding the exact role of TLRs. We aimed at characterizing the ... Read more >>

Haematologica (Haematologica)
[2015, 100(11):1460-1468]

Cited: 8 times

View full text PDF listing >>



Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.

Andreas Agathangelidis, Lydia Scarfò, Federica Barbaglio, Benedetta Apollonio, Maria Teresa Sabrina Bertilaccio, Pamela Ranghetti, Maurilio Ponzoni, Gabriella Leone, Valeria De Pascali, Lorenza Pecciarini, Paolo Ghia, Federico Caligaris-Cappio, Cristina Scielzo,

PLoS ONE (PloS one)
[2015, 10(7):e0134748]

Cited: 0 times

View full text PDF listing >>



Directing CLL-cell traffic.

Federico Caligaris-Cappio,

Blood (Blood)
[2015, 126(11):1267-1268]

Cited: 0 times

View full text PDF listing >>



Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.

Andreas Agathangelidis, Lydia Scarfò, Federica Barbaglio, Benedetta Apollonio, Maria Teresa Sabrina Bertilaccio, Pamela Ranghetti, Maurilio Ponzoni, Gabriella Leone, Valeria De Pascali, Lorenza Pecciarini, Paolo Ghia, Federico Caligaris-Cappio, Cristina Scielzo,

Immortalized cell lines representative of chronic lymphocytic leukemia (CLL) can assist in understanding disease pathogenesis and testing new therapeutic agents. At present, very few representative cell lines are available. We here describe the characterization of a new cell line (PCL12) that grew spontaneously from the peripheral blood (PB) of a ... Read more >>

PLoS ONE (PloS one)
[2015, 10(6):e0130195]

Cited: 4 times

View full text PDF listing >>



High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

Andrés J M Ferreri, Giovanni Donadoni, Maria Giuseppina Cabras, Caterina Patti, Michael Mian, Renato Zambello, Corrado Tarella, Massimo Di Nicola, Alfonso M D'Arco, Gianluca Doa, Marta Bruno-Ventre, Andrea Assanelli, Marco Foppoli, Giovanni Citterio, Alessandro Fanni, Antonino Mulè, Federico Caligaris-Cappio, Fabio Ciceri,

Treatment of secondary CNS dissemination in patients with aggressive lymphomas remains an important, unmet clinical need. Herein, we report the final results of a multicenter phase II trial addressing a new treatment for secondary CNS lymphoma based on encouraging experiences with high doses of antimetabolites in primary CNS lymphoma and ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2015, 33(33):3903-3910]

Cited: 25 times

View full text PDF listing >>



Aging and blood disorders: new perspectives, new challenges.

Dominique Bron, Lionel Ades, Tamas Fulop, Valentin Goede, Reinhard Stauder, ,

Haematologica (Haematologica)
[2015, 100(4):415-417]

Cited: 4 times

View full text PDF listing >>



Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.

Mark C Lanasa, Leslie Andritsos, Jennifer R Brown, Janice Gabrilove, Federico Caligaris-Cappio, Paolo Ghia, Richard A Larson, Thomas J Kipps, Veronique Leblond, Donald W Milligan, Ann Janssens, Amy J Johnson, Nyla A Heerema, Andreas Bühler, Stephan Stilgenbauer, Jeanne Devin, Michael Hallek, John C Byrd, Michael R Grever,

Early phase studies of alvocidib showed activity in relapsed CLL including patients with high risk genomic features and those refractory to fludarabine. A multi-center, international, phase II study of alvocidib in fludarabine refractory CLL was undertaken to validate these early results. Patients with fludarabine refractory CLL or prolymphocytic leukemia arising ... Read more >>

Leuk. Res. (Leukemia research)
[2015, 39(5):495-500]

Cited: 15 times

View full text PDF listing >>



Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.

Andrés J M Ferreri, Marta Bruno-Ventre, Giovanni Donadoni, Maurilio Ponzoni, Giovanni Citterio, Marco Foppoli, Alessandro Vignati, Lydia Scarfò, Marianna Sassone, Silvia Govi, Federico Caligaris-Cappio,

The most effective strategy to prevent central nervous system (CNS) dissemination in diffuse large B-cell lymphoma (DLBCL) remains an important, unmet clinical need. Herein, we report a retrospective analysis of risk-tailored CNS prophylaxis in 200 human immunodeficiency virus-negative adults with DLBCL treated with rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or similar. ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2015, 168(5):654-662]

Cited: 26 times

View full text PDF listing >>



Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis.

Daniela Belloni, Magda Marcatti, Maurilio Ponzoni, Fabio Ciceri, Lorenzo Veschini, Angelo Corti, Federico Caligaris Cappio, Marina Ferrarini, Elisabetta Ferrero,

Angiopoietin-2 (Ang-2) is involved in angiogenesis in both solid and hematological malignancies. In Multiple Myeloma (MM), serum Ang-2 correlates with disease progression and response to therapy. To address the patho-physiologic role of Ang-2 in MM associated angiogenesis, we used sera from patients with active MM, which contained significantly higher levels ... Read more >>

Exp. Cell Res. (Experimental cell research)
[2015, 330(1):1-12]

Cited: 7 times

View full text PDF listing >>



A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Farrukh T Awan, Peter Hillmen, Andrzej Hellmann, Tadeusz Robak, Steven G Hughes, Denise Trone, Megan Shannon, Ian W Flinn, John C Byrd, ,

Lumiliximab is a chimeric monoclonal antibody that targets CD23 on the surface of chronic lymphocytic leukaemia (CLL) B-cells. Early phase clinical studies with lumiliximab alone and in combination with fludarabine, cyclophosphamide and rituximab (FCR) established its potential efficacy and tolerability. The 152CL201 trial [Lumiliximab with fludarabine, cyclophosphamide and rituximab (FCR) ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2014, 167(4):466-477]

Cited: 12 times

View full text PDF listing >>



Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Francesca Cottini, Teru Hideshima, Chunxiao Xu, Martin Sattler, Martina Dori, Luca Agnelli, Elisa ten Hacken, Maria Teresa Bertilaccio, Elena Antonini, Antonino Neri, Maurilio Ponzoni, Magda Marcatti, Paul G Richardson, Ruben Carrasco, Alec C Kimmelman, Kwok-Kin Wong, Federico Caligaris-Cappio, Giovanni Blandino, W Michael Kuehl, Kenneth C Anderson, Giovanni Tonon,

Oncogene-induced DNA damage elicits genomic instability in epithelial cancer cells, but apoptosis is blocked through inactivation of the tumor suppressor p53. In hematological cancers, the relevance of ongoing DNA damage and the mechanisms by which apoptosis is suppressed are largely unknown. We found pervasive DNA damage in hematologic malignancies, including ... Read more >>

Nat. Med. (Nature medicine)
[2014, 20(6):599-606]

Cited: 97 times

View full text PDF listing >>



Advertisement

Disclaimer
1.2804 s